Cancer Transcriptome Atlas
Designed for comprehensive profiling of the tumor, tumor microenvironment, and tumor immune status, the Cancer Transcriptome Atlas (CTA) is the right tool for any immuno-oncology study. Profile 1800 targets simultaneously with spatial resolution- focused on 55 critical immune and tumor related pathways. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligos via a UV-photocleavable linker. Oligo sequences contain ROI indices mapping them back to tissue location, an RNA target identification sequence mapping them back to their ISH probes, and a unique molecular identifier (UMI) to deduplicate reads. Sequencing files are integrated back to slide images and ROI selections for spatially resolved RNA expression analysis.
Let Canopy run the CTA assay for you with our GeoMx DSP services, and deliver the data right to your inbox, getting you publishable data faster- inquire today about your next project!
Profiling over 1800 RNA targets simultaneously with spatial resolution in any region of interest from a single tissue section
ISH probes are conjugated to DNA-indexing oligos; these oligos contain ROI indices mapping them back to their tissue location, an RNA target ID sequence matching them to their ISH probes, and a UMI to dedup reads
Comprehensive RNA content designed for cancer biology research in any tissue
Canopy's GeoMx DSP Service includes consultative discussions with our team for ROI selection and data QC and analysis overview
Details & Data
Curated Content for Cancer Biology
The CTA panel for GeoMx DSP is designed to profile all aspects of tumor and tumor microenvironment biology. Use this assay to:
- Profile global immune response
- Assess microenvironment immune activity
- Quantify tumor reactivity to the immune response and therapeutic treatments
- Measure clinically-derived gene sets including the 18-gene Tumor Inflammation Signature (TIS) known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade, and the PAM50 signature known to be associated with breast cancer metastasis.
|Annotation||# Genes||Annotation||# Genes||Annotation||# Genes||Annotation||# Genes|
|Angiogenesis||51||CT Antigens||31||Insulin Signaling||64||Notch Signaling||78|
|Antigen Presentation||104||Costimulatory Signaling||48||Interferon Signaling||89||Nucleic Acid Sensing||80|
|Apoptosis||62||Cytosolic DNA-sensing||30||Inerleukin Signaling||205||PDGF Signaling||34|
|BCR Signaling||79||Death Receptor Signaling||118||Lymphocyte Regulation||89||Proteotoxic Stress||11|
|C-type Lectin Activation||64||DNA Damage Repair||155||Lymphocyte Trafficking||43||Regulation of Cell Motility||90|
|cAMP Signaling||68||ECM Organization||126||MAPK Signaling||220||TCR Signaling||52|
|Carbon Metabolism||48||EMT||81||Matrix Remodeling and Metastasis||115||TGF-beta Signaling||90|
|Cell Adhesion||207||Epigenetic Regulation||58||Metabolism||174||TLR Signaling||90|
|Cell Adhesion Signaling||117||FC Receptor Signaling||58||mTOR Signaling||35||Transcriptional Misregulation||118|
|Cell Cycle||139||FoxO Signaling||82||Myeloid Activity||174||Type I Interferon Signaling||48|
|Chemokine Signaling||119||Hedgehog Signaling||49||Neutrophil Activation||120||Type II Interferon Signaling||49|
|Circadian Clock||19||Hippo Signaling||71||NF-kB Signaling||105||Wnt Signaling||128|
|Complement System||43||Hypoxia||73||NK Cell Activation||108|
Cancer Transcriptome Atlas Assay Design
Assess gene expression data for 1800 gene targets with spatial resolution with the CTA panel. Using morphology marker antibodies, such PanCk and CD45, assess immune profile of tissue to select ROIs. The ISH probes are conjugated to unique DNA-indexing oligos which are UV-photocleaved and then oligo sequences are sequenced on an Illumina sequencer. The DNA oligo sequences contain ROI indices mapping them back to their tissue location, an RNA target identification sequence matching them to their ISH probe, and a UMO to dedupe the reads.
ROI selection is a critical step in the GeoMx DSP workflow. Canopy’s service assists in ROI selection to make sure our clients are generating the best data for their project. Once morphology marker staining is complete, a Canopy scientist will collaboratively review the images with our clients to select the ROIs for the project. The ROIs provide the spatial resolution for the downstream gene expression analysis.
Following ROI selection, the sequences are collected, and library prep begins. Samples are sequenced on the Illumina sequencer. Indices and UMIs on the oligos maintain spatial information and sample specificity. Sequencing data is relayed back to the GeoMx DSP for processing and integration with spatial images.
GeoMx DSP Data Analysis
Canopy’s GeoMx DSP service includes data consultation. Once sequencing data is integrated back to GeoMx DSP instrument, a Canopy scientist schedules a consultation with the client. This session is used to review the QC data from the project and provide an overview on the analysis suite. From there the client should be able to do their own analysis and download data, figures and images for publication.
The GeoMx analysis suite combines whole tissue visualization with advanced ROI selection to enable spatial profiling of tissue sections by tracking the image data to corresponding profiling data. There are a number of normalization options and a variety of data visualization formats to export publication-quality figures.
Complete Coverage for Cancer Biology
Designed for cancer biology research, the CTA provides complete coverage of tumor biology, the microenvironment, and the immune response, without sequencing unnecessary targets.